Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the AD-4833/TOMM40_301 Study With Diagnosis of Mild Cognitive Impairment Due to Alzheimer Disease

NCT02284906 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02284906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02284906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the AD-4833/TOMM40_301 Study With Diagnosis of Mild Cognitive Impairment Due to Alzheimer Disease
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Terminated
Start date
February 12, 2015
Completion date
May 8, 2018
Enrollment
40 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

mild cognitive impairment due to alzheimer's disease